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Abstract 
Objective: Elevated alanine transaminase (ALT) is a strong predictor of metabolic syndrome, but there 
are few data from the Australian population.  We aimed to determine the prevalence of elevated ALT 
and association with metabolic risk factors. 
Methods:  In this cross sectional study including adult participants (N=9,447) from a nationwide, 
population based survey, we assessed the prevalence of elevated ALT [defined as ≥ 40 IU/L (males) and 
≥ 30 IU/L (females) as baseline, and ALT as ≥ 30 IU/L (males) and ≥ 19 IU/L (females) as lower threshold], 
distribution of metabolic risk factors, and independent predictors of elevated ALT in logistic regression 
models. Analyses were weighted to the population with population weights.  
Results: Elevated ALT levels were found in 11.2% of the Australian population. People with elevated ALT 
were younger (43 vs 46 yrs) with more truncal adiposity (100 vs 91 cm), higher pro-atherogenic lipids 
and glucose and exercised less (120 vs 160 minutes per week, p<0.05 for all analyses). Regression 
analyses indicated that younger age, male sex, diabetes, triglycerides, apolipoprotein B and waist 
circumference were independent predictors of elevated ALT. The population attributable fraction of 
elevated ALT due to truncal obesity was estimated at 47%. 
Conclusion & Implications: These data demonstrate a high prevalence of elevated ALT in the general 
population that is closely associated with metabolic risk factors. Individuals with elevated ALT should be 
evaluated for co-existent metabolic disorders.  
 
Keywords: ALT, population, metabolic syndrome, cross sectional study 
 
 
Introduction 
Elevations in alanine transaminase (ALT) are frequently associated with hepatic injury due to viral 
hepatitis, autoimmune hepatitis and nonalcoholic fatty liver disease, the latter predictive of future 
development of metabolic syndrome and type 2 diabetes in some populations(1, 2). Cross sectional data 
suggests that elevated ALT is also strongly associated with components of the metabolic syndrome, with 
a positive, linear correlation of ALT with BMI(3), fasting glucose(4) and pro-atherogenic lipids such as 
apolipoprotein B, VLDL and LDL(5). In addition, prospective data indicates that elevated ALT may predict 
future metabolic syndrome (14% excess risk for every 5 IU/L increase in ALT)(6) and type 2 diabetes(7) 
(16% excess risk for every 5 IU/L increase in ALT) although studies on the relationship of ALT and 
cardiovascular or all-cause mortality are conflicting(8-11) . Similarly, when nonalcoholic fatty liver 
disease (NAFLD) is defined by elevated enzymes (both ALT and GGT), an association is found between 
NAFLD and increased incidence of type 2 diabetes and metabolic syndrome(1, 12). 
 
Despite these data suggesting that ALT may predict incident metabolic diseases, data on the prevalence 
of elevated ALT in the Australian population is scarce. Examination of evidence from the 1994 Busselton 
Health Survey, a population based cohort first examined in 1966 and followed through to 1994, 
suggested that elevated ALT was associated with metabolic syndrome and an overall prevalence of 
elevated ALT of 5.2%(13). Data from large epidemiological studies in the United States suggest that 
elevated ALT has been increasing, estimated at 7% in 1988(14), 8.9% in 1999 and 11% in 2008 (15), while 
studies in Asian populations where viral hepatitis is common, show a prevalence from 7.4% to 11.4%(16, 
17).  
 
The primary aims of this cross sectional study were to assess the prevalence of elevated ALT in the 
Australian population as a whole and in high risk subgroups including those with elevated BMI or waist 
circumference(18).  We also aimed to determine the strongest metabolic predictors of elevated ALT, and 
to estimate the risk of elevated ALT attributable to truncal obesity using the population attributable 
fraction method.  
 
METHODS 
Survey design and conduct 
The Australian Health Survey is a nationwide, population based survey conducted throughout 2011-
2012. A detailed description of the survey methodology is provided elsewhere(19). Briefly, the survey 
used a multistage, stratified, probability sampling technique to identify random households within 
clusters that were representative of 97% of the Australian population. Within each cluster, homes were 
selected and approached for participation with introductory letters. In the event of non-response, five 
call backs were attempted before a household was classified as non-responding. Pre-specified exclusions 
were persons of Indigenous background (who were studied separately), people living in institutions or 
very remote areas, and members of the armed forces. There was no restriction by age. All participants 
provided written informed consent, and ethical approval was granted by the Australian Government 
Department of Health and Ageing’s Departmental Ethics Committee. 
 
Variable measurement  
Trained interviewers used validated questionnaires to collect information on variables known or 
suspected to influence ALT levels. Clinical history included age, sex and smoking status (current, ex-
smoker or never user).Diabetic status was recorded according to whether respondents had ever been 
told by a doctor or nurse that they had diabetes or high glucose. For physical activity data, information 
was collected on both the average minutes of physical activity for fitness, recreation, sport or transport 
in the last week, and whether participants met recommended guidelines of ≥150 minutes/week of 
moderate exercise (i.e. that which incurred a moderate increase in physical exertion and heart 
rate/breathing, excluding walking). Blood pressure was recorded with two measurements on the left 
arm obtained while seated, using an appropriately sized cuff on an automated monitor. The second 
recording was used unless the difference was > 10mmHg, then a third measurement was taken and the 
second and third readings were averaged. Weight was determined by digital scales and a stadiometer 
measured height in centimetres. Body mass index (BMI) was calculated as weight/height2 (kg/m2). Waist 
circumference was taken at the midpoint between the lowest rib and top of iliac crest as per World 
Health Organization recommendations using a metal tape measure, where a waist circumference ≥ 
80cm for women and ≥ 94cm for men was considered “increased risk” and ≥88cm for women or ≥102 
cm for men was considered “substantially increased risk”. For a subgroup of participants, adherence or 
non-adherence to recommended alcohol consumption guidelines of ≤20g/day on any given day was also 
recorded. 
 
Fasting blood samples were collected in the morning by qualified phlebotomists either at home or the 
nearest Sonic Healthcare collection centre and analysed centrally in < 72 hours by Douglass Hanly Moir 
Pathology as a fresh sample. Samples were taken over a 12 month period to take into account seasonal 
variation. Serum ALT (U/L), GGT (U/L), triglycerides (mmol/L), high density lipoprotein (HDL, mmol/L), 
low density lipoprotein (LDL, mmol/L) and ferritin (μg/L) were analysed using an Architect Ci16200 
analyser (Abbott Diagnostics). Serum apolipoprotein B (g/L) was analysed using an Integra 800 analyser 
(Roche Diagnostics), and fasting glucose was measured in mmol/L using the hexokinase method (Integra 
800 analyser, Roche Diagnostics). Vitamin D was measured as serum 25-hydroxy vitamin D using a mass 
spectrometry method, with levels ≥50 nmol/L considered adequate. 
 
Determination of the threshold for an elevated ALT 
As there is no consensus on what level constitutes an elevated ALT, the threshold was determined 
consistent with levels reported previously(20), and in accordance with the testing laboratory’s reference 
range at  ALT ≥ 30 IU/L for females and ≥40 IU/L for males(21). Baseline analyses were undertaken using 
these levels, and further analyses were repeated using a lower threshold that has been proposed in the 
literature (ALT ≥ 19 for females and ALT ≥ 30 for males)(22) to explore whether a lower threshold led to 
the same or different results. 
 
Population attributable fraction 
The population attributable fraction is a public health statistic that describes the contribution of a risk 
factor to a disease; in this case, the contribution of truncal obesity to the prevalence of elevated ALT, as 
this is known to be one of the strongest predictors(20). It is calculated by the following equation: 
Fraction     =  θ (Relative Risk-1) 
            1 + θ (Relative Risk -1) 
where θ represents the proportion of people who have truncal obesity (waist circumference  ≥ 80cm for 
females and ≥94cm for males), and relative risk is approximated by the adjusted odds ratio of elevated 
ALT in people with truncal obesity compared to those with a normal waist circumference. The 
population attributable fraction is useful for public health physicians and policy makers in determining 
the most important risk factors to target when addressing a problem of public health significance.  
 
Statistical analysis 
The prevalence of elevated ALT was estimated in the overall Australian population, and according to sex, 
BMI and waist circumference, as the latter are recognised as the strongest risk factors for development 
of metabolic diseases(23, 24).  The population was then divided into 2 groups of normal versus elevated 
ALT, and the means of variables known or suspected to be associated with ALT levels were compared 
between groups. The t-statistic was used to test for a difference between normally distributed variables. 
For non-Normally distributed variables (serum triglycerides, ferritin and minutes per week of exercise) 
log transformations were undertaken and the means compared using the t-statistic. Proportions were 
compared using the chi-square statistic. Analyses were weighted to the general Australian population by 
the use of population weights as recommended by the Australian Bureau of Statistics (ABS) (25) . A set 
of 60 population weights are supplied by the ABS to facilitate a delete-a-group Jackknife approach to 
standard error estimation, to take into account the cluster design of the survey. This allows for 
extrapolation of study results to the wider population. Univariate logistic regression analyses were 
undertaken to assess the strength and direction of relationships between elevated ALT and explanatory 
variables. Variables which had a positively skewed non-Normal distribution were log transformed, and 
assumptions of linearity checked graphically, with all variables found to be linear. Multivariable logistic 
regression analysis was performed with the inclusion of all potential explanatory variables (excluding 
ferritin, Vitamin D and BMI as the latter demonstrates collinearity with waist circumference) in the 
baseline model and backwards stepwise elimination undertaken until all remaining variables were 
significant at the p<0.05 level. Additional models were fitted to determine whether the variables 
selected for inclusion in the final model were sensitive to their coding as continuous or categorical (for 
diabetes, we used diabetic status or fasting glucose; for exercise we used minutes of exercise/week or 
whether participants adhered to exercise guidelines of > 150 minutes/week, and for waist 
circumference, we tested mean waist circumference or whether participants were in normal or at-risk 
categories). As the results were consistent irrespective of type of coding, categorical variables for 
diabetes and waist circumference category are presented in the final models. A two-way interaction 
term between age and sex was investigated in the baseline model but found to be not significant. 
Similar analyses were performed for the relationship between elevated GGT (defined as ≥ 50 U/L for 
males and ≥ 35 U/L for females) and metabolic co-factors, and are included as supplementary data (see 
supplementary tables). A p value <0.05 was considered statistically significant, and all analyses were 
undertaken in SAS v9.3 (SAS Institute, Cary, NC). 
 
RESULTS 
Study cohort and prevalence of elevated ALT 
Of 27,636 people who participated in interviews, 10,184 provided blood samples and 9,447 were aged ≥ 
18 and formed our study cohort (Figure 1). The majority (80%) of blood samples were fasting. The 
prevalence of elevated ALT in the Australian population overall was 11.2%, and higher for males (13.9%) 
than females (8.4%). The prevalence of elevated ALT was higher in people who were overweight or 
obese, estimated at 11.8% and 19.6% respectively, and increased in association with waist 
circumference (Figure 2). When the threshold for elevated ALT was lowered to 30 IU/L (males) and 
19IU/L (females), the overall prevalence of elevated ALT was 32.1%, equivalent to approximately 1/3 of 
the Australian population. 
 Metabolic and demographic characteristics in those with normal and elevated ALT 
People with an elevated ALT were more likely to be younger (43.3 vs 46.4 years), with higher BMI (30.0 
vs 26.9 kg/m2) and greater waist circumference (for males, 103.6 vs 96.1 cm and for females  93.6 vs 
86.4cm). People with elevated ALT had increased levels of LDL and triglycerides, and undertook less 
exercise (221 vs 245 minutes/week)(Table 1). Mean systolic blood pressure was higher in those with 
elevated ALT (124 vs 121 mmHg), although smoking habits were similar in both groups. For the 
subgroup where alcohol data were available (n=5602), the proportion of people who exceeded national 
alcohol guidelines of >20g/day were not significantly different. Demographic characteristics were also 
compared when the threshold for elevated ALT was lowered to ALT 30 IU/L for males and 19 IU/L for 
females. Age and amount of exercise was similar in people with normal or elevated ALT, but the group 
with elevated ALT continued to show significantly higher levels of important metabolic risk factors such 
as BMI, waist circumference and LDL (Table A, Supplementary material).  
 
Univariate and multivariable analyses using standard threshold  
In univariate analyses, the strongest associations with elevated ALT were seen with male sex, 
triglycerides, apolipoprotein B and elevated waist circumference (Table 2). In the multivariable model, 
variables in the final model that remained independent predictors of elevated ALT after controlling for 
other predictors were younger age, male sex, presence of diabetes and higher triglycerides, 
apolipoprotein B, ferritin and elevated waist circumference (Table 2, Figure 3); of these, a substantially 
increased waist circumference (≥ 88cm for women and ≥102cm for men) was the most strongly 
associated predictor. Smoking habits, physical activity levels and blood pressure were not independently 
associated with elevated ALT.  
 Univariate and multivariable analyses using the lower ALT threshold (ALT 30 IU/L males, 19 IU/L 
females) 
In univariate models, age, smoking status and exercise levels were not associated with elevated ALT, 
although similar associations to those seen for the standard threshold were demonstrated for other 
metabolic variables. As compared to the final multivariate model for the standard threshold, the final 
model also included blood pressure, however the effect of other independent variables such as 
increased waist circumference and triglycerides was similar (Table 3).  
 
Population attributable fraction of truncal obesity to elevated ALT 
The proportion of the Australian population with truncal obesity was 0.69, and the relative risk of 
elevated ALT in truncal obesity was approximated by the adjusted odds ratio of elevated ALT in those 
with waist circumference in the “at increased risk” or “substantially increased risk” categories, 
compared to those with a normal waist circumference (O.R. = 2.3).The population attributable fraction 
of truncal obesity to elevated ALT was calculated at 47%, indicating 47% of the risk of elevated ALT 
would be eliminated if all patients had waist circumference in the “not at risk” category.  
 
DISCUSSION 
The findings of this general population based study, derived from 9,447 measurements of ALT in 
community dwelling adults, indicate a high prevalence of elevated ALT at 11.2% for the overall 
population, 13.9% for males and 8.4% for females. The strongest determinant of elevated ALT was an 
increased waist circumference, with risk proportional to size. Other independent predictors were pro-
atherogenic lipids such as serum triglycerides and apolipoprotein B. Male sex was positively associated 
with higher ALT levels, while age was negatively associated, consistent with previous data(26), and may 
be explained by a loss of skeletal muscle mass in elderly populations as some ALT is muscle-derived; 
others propose that ALT may be a novel biomarker of ageing(27). Alcohol intake and exercise were not 
independently associated with ALT in our study, and the impact of exercise on ALT remains 
controversial, with some data suggesting that increased exercise reduces ALT(28, 29), while other data 
do not support this after adjustment for co-factors such as BMI(3).  
 
As there has been a proposal to revise the threshold for elevated ALT downwards(15), we explored the 
use of a lower threshold, derived from the statistical mean ALT in young cohort with no metabolic risk 
factors, and its impact on independent predictors (22). Using a lower threshold resulted in 1/3 of the 
general population classified as having an elevated ALT. The group with elevated ALT continued to 
demonstrate a higher level of metabolic risk factors such as waist circumference, although age and 
exercise levels were not different, suggesting that perhaps the higher threshold teased out subtle 
differences in these characteristics.  In regression analyses, the independent predictors of elevated ALT 
were similar using either threshold. Lowering thresholds for disease detection results in a trade-off of 
increased sensitivity but reduced specificity, and may be useful for detecting a disease where there is a 
readily available, inexpensive and highly effective treatment.  However, given the underwhelming 
efficacy of pharmacotherapy of obesity related diseases, the cost of targeting 1/3 of the population, and 
the absence of a threshold that accurately predicts clinically important sequelae, we contend that there 
remains insufficient data to justify a lower threshold at present.  
 
While the nature of our data does not allow assumptions of causality, the most likely reason for the 
increasing prevalence of elevated ALT is liver fat, known as non-alcoholic fatty liver disease (NAFLD), 
which has increased in parallel with the obesity epidemic. The prevalence of other causes of elevated 
ALT such as viral hepatitis and autoimmune hepatitis have remained unchanged in the population(30).  
As ALT is consistently predicted by obesity, we assessed the contribution of truncal obesity to elevated 
ALT by calculating the population attributable fraction. This was estimated at 47%, suggesting that 47% 
of the risk of elevated ALT would be eliminated if all patients had waist circumference in the “not at risk” 
category. This information is useful for policy makers and public health planners estimating the impact 
of obesity on liver health in the general population, given that data from countries with similar obesity 
demographics suggests that NAFLD will be the primary cause for liver transplantation by 2020(31).   
 
Our results are consistent with reports of a high prevalence of elevated ALT in developed countries, 
estimated at 11% in US populations(15), and higher than historical cohorts from 1988 of 7.9%(14). The 
prevalence of elevated ALT has previously been estimated at 5.2% in a small (n=384) Australian 
population health survey from 1995, which is substantially lower than our findings(13). Studies that have 
assessed independent predictors of elevated ALT in diverse populations have also found obesity to be a 
major determinant in Caucasian(20), Hispanic(32) and Asian populations (17, 33), and 
hypertriglyceridemia is also consistently associated(32). Fasting insulin may also predict ALT(20) 
however this was not available in our study for evaluation. We did not find alcohol to be an independent 
predictor of ALT activity, in line with previous data indicating that BMI influences ALT levels significantly 
more than alcohol(34). While the bulk of available data consistently shows ALT to be a reliable and 
reproducible marker of metabolic health, whether it could prove clinically useful in prediction of 
diseases such as diabetes is unclear. A single study where ALT was added to variables of the German 
Diabetes Risk Score shows a small incremental benefit in diabetes prediction(35), however this area 
requires further exploration. 
 
This study has a number of strengths. It provides Australian data on the prevalence of elevated ALT and 
metabolic cofactors, and a benchmark for future comparison. The large sample size allowed a precise 
estimation of the relationship between ALT and cofactors, and weighting of statistical analyses allowed 
us to make inferences about the Australian population at large. Comprehensive data on alcohol and 
exercise was included in the models, and different variable formats tested, yet results were unchanged, 
strengthening the conclusion that alcohol intake is not a strong predictor of elevated ALT. A major 
limitation to this study is its cross-sectional design which does not allow inferences on causality or the 
temporal nature of relationships, however such large studies are challenging to conduct in a longitudinal 
format. Furthermore, as this cross sectional study has only just been completed, there has not been 
linkage to morbidity or mortality records which could provide information on longitudinal associations. 
The impact of residual selection bias on our results is also difficult to determine, despite techniques to 
minimise this such as five callbacks before non-response was recorded. Finally, misclassification of the 
cause of elevated ALT may have occurred due to misreporting of alcohol consumption or viral hepatitis. 
Serological testing for viral hepatitis was not performed,  however the incidence of Hepatitis B and C 
infections in the Australian population has been reducing over the last decade(36) and misclassification 
due to viral hepatitis is unlikely to affect our conclusions. 
 
Conclusion 
These data indicate a high prevalence of elevated ALT in the general population, which is tightly 
associated with multiple metabolic risk factors. Community dwelling individuals with elevated ALT 
should be assessed for presence of co-existing risk factors that may impact their metabolic health, and 
at a public health level, ALT may be regarded as an additional marker of impaired metabolic health. 
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